Solvay H, Kahn M, Cloarec M, Van De Merckt J, Sneppe R, Schram E, Fenollar J V
Angiology. 1986 Mar;37(3 Pt 1):175-84. doi: 10.1177/000331978603700306.
This study demonstrates the presence of PGI2 in blood and its influence on platelet retention tests, possibly by the intermediate of a releasing system in the columns, which is followed by a proximate recuperation on the erythrocyte sites after the passage. The presence of prostacyclin on the erythrocyte sites seems to depend upon the red cell deformability in relation to the good condition of their erythrocyte ATP reserve. The load of the erythrocyte sites increases with the daily dose of dipyridamole. The maximum load of the sites appears to be reached with a daily dose of dipyridamole 450 mg. Approximately 10% of the atherosclerosis patients who have been treated by dipyridamole keep their platelet hyperaggregability and their abnormally lowered prostacyclin level.
本研究证明了血液中存在前列环素（PGI2）及其对血小板滞留试验的影响，这可能是通过柱内释放系统介导的，随后在血液通过后红细胞部位会迅速恢复。红细胞部位前列环素的存在似乎取决于红细胞的变形能力及其红细胞ATP储备的良好状态。红细胞部位的负荷随着双嘧达莫的日剂量增加而增加。每日双嘧达莫剂量为450毫克时，似乎能达到部位的最大负荷。在接受双嘧达莫治疗的动脉粥样硬化患者中，约10%的患者仍存在血小板高聚集性以及前列环素水平异常降低的情况。
